Table 1.
Clinicopathological characteristics of the melanoma cohort treated with anti-PD-1 therapy
| Characteristic | Anti-PD-1 patients, No. (%) | Objective response rate (CR/PR), No. (%) | Disease control rate (CR/PR/SD), No. (%) |
|---|---|---|---|
| Overall | 116 (100) | 54 (47) | 80 (69) |
| Age (y) | |||
| < 65 | 66 (57) | 33 (61) | 50 (62) |
| ≥ 65 | 50 (43) | 21 (39) | 30 (38) |
| Sex | |||
| Male | 69 (59) | 34 (63) | 47 (58) |
| Female | 47 (41) | 20 (37) | 33 (42) |
| Treatment | |||
| Pembrolizumab | 41 (35) | 20 (37) | 30 (38) |
| Nivolumab | 18 (16) | 7 (13) | 9 (11) |
| Ipilimumab plus nivolumab | 57 (49) | 27 (50) | 41 (51) |
| Prior immune checkpoint blockade | |||
| Yes | 36 (31) | 14 (26) | 23 (29) |
| No | 80 (69) | 40 (74) | 57 (71) |
| Mutation status | |||
| BRAF | 39 (33) | 19 (35) | 27 (34) |
| NRAS | 18 (16) | 8 (15) | 11 (14) |
| KIT | 2 (2) | 1 (2) | 2 (2) |
| None detected | 57 (49) | 26 (48) | 40 (50) |
| Stage at diagnosis | |||
| I | 24 (21) | 14 (26) | 19 (24) |
| II | 23 (20) | 12 (22) | 16 (20) |
| III | 38 (32) | 16 (30) | 24 (30) |
| IV | 20 (17) | 6 (11) | 13 (16) |
| Not available | 11 (10) | 6 (11) | 8 (10) |